If you're considering NAD+ therapy, figuring out the right NAD+ dosage—how much to take and how often—is one of the most important decisions in the process. Like most therapies involving cellular biology, the answer isn't the same for everyone. Here's a practical overview of typical NAD dosing protocols and how providers determine the right approach for individual patients.

Why NAD+ Dosing Is Individualized

There's no universal standard for how much NAD+ a person should receive. Dosing depends on the delivery method (IV, injection, or oral precursor), your age and baseline NAD+ levels, your overall health and metabolic status, what you're trying to achieve, and how your body responds to initial treatments. A 35-year-old seeking energy optimization will likely have a different protocol than a 55-year-old addressing significant fatigue and cognitive decline. This is why a qualified provider's assessment is essential before starting therapy.

Typical Dosing for NAD+ Injections

Subcutaneous NAD+ injections are one of the most common delivery methods for ongoing therapy. Typical doses range from 50 mg to 200 mg per injection, administered two to three times per week during a loading phase and then reduced to once or twice weekly for maintenance. Some protocols use higher doses, but providers generally start conservatively and adjust based on your response and tolerance.

The loading phase, which typically lasts two to four weeks, is designed to rapidly restore NAD+ levels. The maintenance phase that follows aims to keep those levels stable over the long term with less frequent dosing.

Typical Dosing for NAD+ IV Infusions

IV NAD+ protocols generally use higher doses per session because the treatment occurs less frequently. A common range is 250–500 mg per infusion, with some protocols going up to 750 mg or higher. These sessions typically occur once or twice per week during a loading phase, and then monthly or as needed for maintenance.

The higher per-session dose is possible because IV delivery provides immediate access to the bloodstream. However, higher doses also increase the likelihood of infusion-related side effects, which is why experienced providers titrate carefully.

Oral NAD+ Precursor Dosing

For patients using oral NMN or NR, typical daily doses range from 250 mg to 1,000 mg. Most clinical studies have used doses in the 250–500 mg range and found them safe and effective for raising NAD+ levels. These are taken daily as capsules and are the simplest option from a logistics standpoint, though absorption efficiency is lower than with injection or IV delivery.

How Providers Adjust Your Protocol

A well-managed NAD+ protocol isn't static. Your provider should monitor your response through a combination of symptom assessment (energy, cognition, sleep, recovery) and, ideally, lab work to measure NAD+ metabolites or related biomarkers. If your symptoms are improving and you're tolerating the therapy well, the maintenance dose holds. If the response is insufficient, the dose or frequency may be increased. If side effects emerge, adjustments are made downward.

Finding the Right Balance

The goal of NAD+ dosing is to restore cellular NAD+ levels to a range that supports optimal function without overshooting. More isn't always better—the objective is the minimum effective dose that produces meaningful benefits with minimal side effects. Your provider's expertise and your body's feedback are the two most important guides in this process.

At HRT Wellness, we design NAD+ protocols individually for each patient, starting with a baseline assessment and adjusting as treatment progresses. Schedule a consultation to discuss what dosing approach might work best for you.

References

  1. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+. Nature Communications. 2018;9(1):1286.
  2. Yoshino J, Baur JA, Imai S. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism. 2018;27(3):513–528.
  3. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules. Cell. 2018;154(6):1350–1364.